Сутацимиг

Prop. INN (наименование, предложенное ВОЗ)

2933972-64-4

immunoglobulin (H-gamma4_L-kappa)_( H-gamma4_L-kappa), anti-[Homo sapiens F7 (coagulation factor 7, blood coagulation factor VII, coagulation serum prothrombin conversion accelerator) activated (F7a, F7A, FVIIa, FVIIA)] and anti-[Homo sapiens TREML1 (triggering receptor expressed on myeloid cells like 1, TREM-like transcript 1, TLT1, TLT-1)], humanized monoclonal antibody, bispecific, bivalent;
H-gamma4 heavy chain anti-F7a humanized (1-448) [VH (Homo sapiens IGHV4-30-2*07 (92.9%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [9.7.15] (26-34.52-58.97-111)) (1-122) -Homo sapiens IGHG4*01 nG4m(a) CH2 L92, G4v5 h P10, G4v10 CH3 L85.1, K88 (CH1 (123-220), hinge 1-12 S10>P (230) (221-232), CH2 L92 (311) (233-342), CH3 F85.1>L (407), R88>K (411) (343-447), CHS K2>del (448)) (123-448)], (136-214')-disulfide with L-kappa light chain humanized anti-F7a (1'-214') [V-KAPPA (Homo sapiens IGKV3D-11*01 (88.8%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')];
H-gamma4 heavy chain anti-TREML1 humanized (1''-440'') [VH (Homo sapiens IGHV3-74*01 (89.7%) -(IGHD) -IGHJ5*01 (92.9%), CDR-IMGT [8.8.7] (26''-33''.51''-58''.97''-103'')) (1''-114'') -Homo sapiens IGHG4*01 nG4m(a) CH2 L92, G4v5 h P10 (CH1 (115''-212''), hinge 1-12 S10>P (222'') (213''-224''), CH2 L92 (303'') (225''-334''), CH3 (335''-439''), CHS K2>del (440'')) (115''-440'')], (128''-219''')-disulfide with L-kappa light chain, anti-TREML1 humanized (1'''-219''') [V-KAPPA (Homo sapiens IGKV2-24*02 (91.0%) -IGKJ2*01 (100%), CDR-IMGT [11.3.9] (27'''-37'''.55'''-57'''.94'''-102''')) (1'''-112''') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (158'''), V101 (196''')) (113'''-219''')]; dimer (228-220'':231-223'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Поделиться этой страницей